Answers are grounded in this paper and cite their sources.
Pd-based catalysts were prepared by successive wet impregnation of γ-Al 2 O 3 with aqueous solutions of Ni, Co and Pd nitrates: Ni and Co were first co-deposited from a mixed solution, followed by Pd introduction in a second impregnation step. They were characterized by X-ray diffraction (XRD), X-ray photoelectron spectroscopy (XPS), temperature programmed reduction (TPR), temperature programmed oxidation (O 2 -TPD), X-ray fluorescence measurements (XRF), BET method. The variation of the nickel content during the synthesis of the PdNix0.5Co/Al 2 O 3 catalysts leads to the formation of different oxide phases on the surface. At nickel contents up to 1 wt%, the main phases are NiO weakly interacting with the support and NiAl 2 O 4 and CoAl 2 O 4 . As the nickel content increases, strongly non-stoichiometric oxide phases appear, consisting of NiO moderately interacting with Al 2 O 3 and mixed Ni–Al phases. Pd 0 , Pd 2+ and Pd 4+ species are all observed on the surface of the catalysts calcined at 450 °C, whereas calcination of the cobalt- and nickel-modified support at 800 °C results in the formation of aluminate phases on the surface and the stabilisation of palladium as PdO. The highest activity of the catalyst containing 5 wt% Ni is very likely a result of the good contact of PdO with nickel aluminate and NiO. High-temperature calcination at 800 °C enhanced the catalytic activity of the catalyst with the lowest nickel content, owing to the increased amount of nickel aluminate on the surface.
No takes yet. Share an insight, caveat, or question.
Todorova et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: